Elizabeth Holmes’s Lawyers Attack Prosecution Expert Witness
(Bloomberg) -- Lawyers for Elizabeth Holmes attacked the credibility of an Ivy League medical school professor who prosecutors want to testify at her upcoming criminal trial, arguing he's being used to “parrot” a potentially more damaging witness -- an ex-Theranos Inc. laboratory director.
For a second day, Holmes and her lawyers appeared in-person Wednesday in the federal court where the Theranos founder and former chief executive officer is scheduled to go to trial in August on charges that the blood-test startup once valued at $9 billion was a fraud. U.S. District Judge Edward Davila in San Jose, California, is winnowing the evidence and testimony jurors will consider.
Holmes claimed Theranos blood-test results were of the “highest accuracy,” Assistant U.S. Attorney Robert Leach told Davila. The testimony of Stephen Master, an associate professor of pathology and laboratory medicine at the University of Pennsylvania's Children's Hospital of Philadelphia, “puts the lie to that,” Leach said.
After Davila extinguished an attempt by Holmes's lawyers to knock Master out entirely as a witness, concluding he's qualified to testify about blood-testing industry standards, they set about trying to curtail his testimony.
Read More: The Spectacular Rise and Fall of Elizabeth Holmes and Theranos
Though Master dominated the discussion, the arguments offered a peek at how government prosecutors intend to use him to corroborate and amplify the testimony of another, potentially more significant witness: former Theranos lab director Adam Rosendorff.
Rosendorff is an inherently dangerous witness to Holmes because he was a high-level insider with direct contact and communications with her. Prosecutors say that in November 2014, Rosendorff complained to Holmes that he was being pressured to vouch for blood-test results he didn't believe in. They've also said he'll testify about the increasing number of complaints about results from Theranos customers in that period.
Leach told Davila at Wednesday's hearing that Rosendorff eventually resigned “out of concern that Theranos was turning a blind eye to all of its problems.”
Prosecutors want Master to help the jury's “understanding” of Rosendorff's complaints, according to a court filling.
Amy Saharia, a lawyer for Holmes, told Davila that Master's opinions about certain blood tests, including those for chloride, sodium, and potassium, are “based on emails and customer complaints” and are “not a scientifically valid way to reach conclusions.”
The judge earlier said he has “some problems” with Master's testimony about those particular tests.
Read More: Theranos Founder Can Lean on Silicon Valley Swagger in Defense
Master's opinions about other tests, for cholesterol and vitamin D, reach beyond the academic articles he relied on to form his conclusions, Saharia argued.
The lawyer reinforced Davila's decision that a separate hearing is required down the road devoted to Master's testimony. Saharia told Davila she intends to ask Master “how he was able to reach an opinion that the study's authors didn't reach.”
Saharia also sought to block Master from telling jurors about blood-testing industry standards. The case hinges on whether Holmes lied about the accuracy and reliability of Theranos blood tests, not about whether Theranos violated regulations or operated within industry standards, she told Davila.
Master is being used to “parrot Dr. Rosendorff,” and “in some instances after the fact, which doesn't reflect Dr. Rosendorff's real-time assessments,” Saharia said. “His opinions don't fit the case.”
The case is U.S. v. Holmes, 18-cr-00258, U.S. District Court, Northern District of California (San Jose).
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.